

## **BIIB021**

Cat. No. CEI-0987

Lot. No. (See product label)

## Introduction

Description BIIB021 is an orally available, synthetic small-molecule Hsp90 inhibitor. It binds in the ATP-binding pocket

of Hsp90 (Ki =  $1.7\pm0.4$  nM) and induces HER-2 degradation with an EC50 of  $38\pm10$  nM in MCF-7 cells. It ncreases expression of the heat shock proteins Hsp90 $\alpha$  and Hsp70, but has no effect on expression of the nonclient protein phosphatidylinositol 3-kinase p85 subunit. BIIB021 inhibits the proliferation of N87, MCF-7, and BT474 tumor cells with IC50 values of 0.06, 0.31, and 0.14  $\mu$ M, respectively. It has significant antitumor activity in N87 stomach, BT474 breast, CWR22 prostate, U87 glioblastoma, SKOV3 ovarian, and

Panc-1 pancreatic tumor xenograft models.

Synonyms EL52, HSP86, HSP89A, HSP90A, HSP90N, HSPC1, HSPCA, HSPCAL1, HSPCAL4, HSPN, Hsp89, LAP2

## **Product Information**

**Appearance** Off-white or light brown powder

*CAS No.* 848695-25-0

Molecular C14H15CIN6O

Formula

Molecular

318.8 Da

Weight

*Purity* >99%

Targets HSP90

**IC50** N87, MCF-7, and BT474 tumor cells: IC50 0.06, 0.31, and 0.14 μM, respectively

**Soluble** in DMSO at 65 mg/ml; soluble in ethanol at 3 mg/ml with warming; very poorly soluble in water;

maximum solubility in plain water is estimated to be about 50-100  $\mu M$ .

## Storage and Shipping Information

Stability Store at or below -20°C. Solid form is stable at least 12 months from date of receipt, when stored as

directed. Do not store aqueous solutions for more than one day.

1/1